Dihydroartemisinin is widely used as an intermediate in the preparation of other artemisinin-derived antimalarial drugs, is recommended as the first-line anti-malarial drug with low toxicity. Dihydroartemisinin possesses promising anticancer activities and induce cancer cell death through apoptotic pathways.

H-Gly-Arg-Ala-Asp-Ser-Pro-Lys-OH

Isogambogenic acid inhibits angiogenesis and may be a viable drug candidate in anti-angiogenesis therapy.